Developer of cancer vaccines against major cancer types such as colorectal, gastric, and prostate cancer. The cancer vaccines are meant to stimulate the immune system selectively as to help a patient's own systems to react against cancer cells. The vaccines are designed to prevent metastases, thus prolonging survival time. The company also aims for its products to be used in other preventative applications.[Keywords: immunotherapy]
Missing: Igeneon's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Igeneon's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Igeneon Frequently Asked Questions (FAQ)
When was Igeneon founded?
Igeneon was founded in 1999.
Where is Igeneon's headquarters?
Igeneon's headquarters is located at Brunner Strasse 69/3, Vienna.
What is Igeneon's latest funding round?
Igeneon's latest funding round is Acquired.
How much did Igeneon raise?
Igeneon raised a total of $68.9M.
Who are the investors of Igeneon?
Investors of Igeneon include Deutsche Venture Capital, 3i Group, Horizonte Venture Management, Capexit, Burrill & Company and 10 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.